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The participation of minors in biobank research can offer great benefits for science and health care. However, as minors are
a vulnerable population they are also in need of adequate protective measures when they are enrolled in research. Research
using biobanked biological samples from children poses additional ethical issues to those raised by research using adult biobanks.
For example, small children have only limited capacity, if any, to understand the meaning and implications of the research
and to give a documented agreement to it. Older minors are gradually acquiring this capacity. We describe principles for
good practice related to the inclusion of minors in biobank research, focusing on issues related to benefits and subsidiarity,
consent, proportionality and return of results. Some of these issues are currently heavily debated, and we conclude by
providing principles for good practice for policy makers of biobanks, researchers and anyone involved in dealing with stored
tissue samples from children. Actual implementation of the principles will vary according to different jurisdictions.
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Genetic and genomic research has made tremendous advances during
the last decade. Its focus is the discovery of the functioning of genes in
relation to health and disease. Effectively performing such research
requires the study of large populations. Human biological material,
such as blood and other tissue, genetic material in the form of DNA
or RNA and baseline medical data from the donor, are important
prerequisites. Such collections are often referred to as biobanks,
although opinions differ on the precise definition.1–4 In this text we
use the term ‘biobank’ as laid down by the P3G: An organised
collection of human biological material and associated informa-
tion stored for one or more research purposes (http://www.
p3gobservatory.org/lexicon/list.htm).
This document is building on earlier work of the first and last
author, analysing the opinions of stakeholders and analysing ethical
principles.5–10 The current document and the principles for good
practice have been drafted in collaboration with the Public and
Professional Policy Committee of European Society of Human
Genetics (ESHG). They have been posted on the ESHG website
from 12 July 2011 to 31 August 2011 and ESHG members and several
experts have been asked for comments. The final version of the
document and the principles for good practice have been approved by
the ESHG Board on 09 March 2012.
Biobanks
Collections of human biological materials have different origins and
exist in different forms.11 Some are created to study a particular
condition and contain samples from patients with that condition.
Others contain materials originally gathered for diagnostic purposes
which are then partly secondarily used for non-therapeutic basic or
translational research. For example, collections of material in the
genetic centres of regional services or university hospitals contain
material ascertained for diagnosis or management, but the ‘left-over’
samples could form a valuable resource for research into specific
conditions.
Population or cohort studies often also have an associated biobank.
In such studies phenotypic information is collected from a cohort or
specific population and links with genetic variants are investigated.
Longitudinal in nature, they create a resource for future unspecified
research. Existing collections also form a good resource for genetic
epidemiological and other research.
Many biobanks contain samples and information from competent
adults, which enables the contributors to provide individual informed
signed consent. The ethical issues related to the use of stored tissues
samples for genetic research have been amply discussed in the
literature, and involve the need for consent, the scope of consent,
the need for privacy protection, the feedback of individual results and
issues related to commercialisation of findings. In the past, complete
anonymization of samples, making it impossible to trace back the
identity of the original donor of the sample, has been recommended
to avoid problems related to certain of these issues. As anonymization
would avoid privacy breaches, it was often suggested as a way to allow
reuse of existing collections, where donors were hard to trace. Today,
with the advent of whole-genome sequencing, some have argued that
complete anonymization becomes impossible. Also, there are certain
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drawbacks: it does not allow recontacting people for follow-up
research or if individual results are shared. Therefore, the use of
coded samples, where individual researchers do not have access to the
identity of the donor, is now more common.
Children in research
In the last century, the status of children has changed significantly and
a number of rights unique to children have come to be recognised.
This is defined in the 1989 Convention on the Rights of the Child,12
which is an internationally legally binding document containing
principles founded on respect for the dignity and worth of each
child, regardless of race, colour, gender, language, religion, opinions,
origins, wealth, birth status or ability. An aim of the Convention is to
protect children, to help secure their basic needs and to enhance the
possibility of reaching their best potential.
The recognition of the rights of children has changed in medical
research as well, following several high profile research studies
exhibiting malpractice, and little respect for children’s rights and
concerns.13 As a result of these, children are now considered to be in
need of extra protection due to their vulnerability. In this document,
we shall use the term ‘minor’ to denote individuals from birth till they
reach the age of majority. We are aware that the legal definition of
‘minor’ varies by country.
Genetic or genomic research on archived samples from children is
useful. Much genetic research combines the study of DNAwith that of
medical and lifestyle data, and data starting from childhood enables
long-term research. Many common conditions such as allergies,
asthma, food intolerance, diabetes and obesity have a multifactorial
aetiology and can often be attributed to a combination of genetic and
environmental or lifestyle factors. Also the rapidly expanding field of
epigenetics explores the influence of in utero exposure, for example,
on gene expression.
There are different forms of paediatric biobanks. Large cohort
studies follow children from birth onwards into adulthood, collecting
phenotypic and lifestyle data together with genetic information. Other
biobanks concentrate on conditions that occur during prenatal life or
childhood, such as congenital defects or childhood cancer, and use
material from children who develop these conditions. Existing
collections, such as newborn blood spot cards, may also form a
useful resource for genetic epidemiological research.14,15
Research on children: principles and ethics of paediatric clinical
trials
Current principles regarding the participation of minors in research
are in many cases laid down in the context of clinical trials. Here, the
principle of minimal risk is often quoted as defining a standard by
which one can decide whether some proposed non-therapeutic
research can be performed with children.16,17 Hence, minimal risk
is understood as a risk that is not higher than what a child would
encounter in everyday life. Moreover, the direct benefits should
counterbalance the risk of a procedure.18 For example, European
normative frameworks for clinical trials (Article 4, Directive 2001/20
EC of the European parliament and of the Council of 4 April 2001)
hold that research on minors should be performed out of necessity,
either because there might be some direct benefit to the participant,
or because the research could benefit children with the same
condition.17 The risks also need to be proportional to the potential
net benefits for the child participating in the clinical trial. Another
concept quoted in the context of clinical trials with minors is that of
subsidiarity: such research should only be done if it cannot be done
on adults.
Research on biological samples from children
Genetic or genomic research using biobanked biological samples from
children poses additional ethical issues to those raised by using adult
biobanks. For example, small children have only limited capacity, if
any, to understand the meaning and implications of the research and
to give a documented agreement to it. Older minors are gradually
acquiring this capacity. Also, the ethical questions are different from
those raised by paediatric clinical trials. Many of the concepts
discussed in the literature on paediatric biobanks, such as minimal
risk and benefit, are deduced from the clinical trials context where the
balancing between risks and benefits is more straightforward, as such
research often may have direct benefit to the participant. In non-
therapeutic biobank research, the question of benefit is more
complex, as in many cases there will not be direct benefit to the
participant, only potential benefits to future patients. Hence, the
amount of risk a research subject is allowed to be subjected to in this
type of research cannot be automatically balanced against the
potential benefit he or she gains from the research. Also, biobanks
facilitate research on stored biological samples rather than on the
child him- or herself, making the procedures less physically risky.
The participation of minors in biobank research can offer great
benefits for science. However, as minors are a vulnerable population
they are also in need of adequate protective measures when they are
enroled in research. In a recent study, researchers have recognised the
need for adequate policies regarding paediatric biobanks.19 In this
document we describe the main issues related to the inclusion of
minors in biobank research, and provide principles for good practice.
It is addressed to policy makers of biobanks, researchers and anyone
involved in dealing with stored tissue samples from children. Where
applicable, we make a distinction between different types of biobanks.
The issues arising from clinical or disease-oriented collections may be
different from those arising from population-based ones. Clinical or
disease-oriented collections may be relatively small in scale, and
patient organisations often have a significant role.20 The aims of
participants and researchers in disease-oriented collections are more
congruent than in population-based biobanks. Also, the ethical issues
arising from the use of samples gathered in a diagnostic setting may
be different from those arising from the use of samples gathered
primarily for research. For example, there is no need to perform extra
venepunctures for research purposes only, and there is often more
direct contact between researchers, who are sometimes also clinicians,
and participants.
Actual implementation of the principles will vary according to
different jurisdictions. For example, in some jurisdictions, written
consent will be necessary for any genetic research on stored tissue
samples, whereas in others it will be enough that participants are
verbally notified. Also, samples may sometimes not be shared across
borders, or may not be completely anonymised. In this document we
focus on the issues related to benefits and subsidiarity, consent,
proportionality and return of results. Hence, there are some elements
we do not address in this document, such as the use of samples by
private companies, patenting and the use of samples from deceased
persons. A proportion of the minors donating biological samples
for genetic research will never reach the age of majority or will never
have legal competence due to their health status. In such cases,
some of the issues described above will not apply or will require
modification.
We shall for each issue describe the general principle, and then give
examples of how these principles may be differently implemented in
different types of biobanks. At the end of the document we have
formulated recommendations.
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BENEFITS AND SUBSIDIARITY
Principle
The requirement of personal benefits, which states that research on
minors can be done if it provides direct benefit to the minor, is
derived from clinical trial ethics and is difficult to transfer to
biobanking. The probability of personal medical benefit to a minor
is small in the case of research using human biological materials. The
requirement of group benefit holds that research on children is
permissible if results of the research may benefit other children with
the same condition. Also the concept of group benefit has been
discussed in the context of biobanking. Some have argued an actual
cure or treatment cannot be immediately derived from genetic
research.8 Others have argued, the possibility of accurate genetic
diagnosis in the future may also be seen as a group benefit.
Some have argued that a minor also gains benefit from being
altruistic while participating in medical research.21 So, even if a child
does not benefit medically from contributing to research, such
research is legitimate, both from a viewpoint of personal benefit as
well as of group benefit. Indeed, a recent line of thought in medical
research stresses the fact that research with and for children is
legitimate, and a focus on the risks does not do justice to either the
participating children or the children benefiting from the research.22
The concept of subsidiarity holds that research on minors should
only be done if the results from research on adults are not transferable
to children. However, this does not limit the research to the study of
paediatric conditions or age-related phenome/genome alterations.
Also late-onset diseases that may be caused by factors that occur
during childhood may be studied, or studies of general genome
variation characteristics that compare age groups in various popula-
tions/environmental conditions and give insights in gene/environ-
ment interactions may generate unique and useful knowledge of
interest. In the case of scarce resources, biological samples from
children could also be used if adult biological samples are unavailable.
CONSENT
Necessity of consent
Principle. A much discussed issue in the context of biobanks in
general is that of consent. With paediatric biobanks, this question is
even more complicated, as small children are typically not able to
provide consent for themselves.23,24 Consent from a parent or a legal
guardian is required for the child’s biological sample to be stored and
used in biobank research (On the P3G website, examples of consent
forms can be found: http://www.p3gobservatory.org/lexicon/list.htm).
Application. When minors are enroled in primary research protocols,
it is straightforward that parents are asked to consent to the
participation of their children in such research, for example, in the
case of longitudinal cohort studies. Parents can be asked to consent at
the time of enrolment. However, in some jurisdictions, this require-
ment may be waved in certain low-risk research, such as research on
anonymised samples, or research on left-over material. In such cases it
may not always be possible or necessary to recontact parents. It may
still be allowable to use such samples in research, provided there is
true oversight and approval of an ethics committee, and specifically
when samples are anonymised this may be the case.
Scope of parental consent
Principle. As minors grow towards maturity the relative importance
of parental consent reduces. The processes of obtaining assent or
consent from adolescents may vary per context and country. Young
people reaching the legal age of majority should have the opportunity
to renew or withdraw consent for storage and use of their samples
and data from biobanks (Of course, the right to withdraw extends
also after a person reaches the legal age of competence). Moreover, as
small children’s wishes cannot be trusted as an expression of their
autonomy and as their preferences may change as they grow older,
there is a risk that certain research would be contrary to their evolving
wishes. This is especially the case when research on stored biological
samples extends over time. In principle, minors have the right to
receive age-appropriate information and agree or disagree (assent or
dissent) about the destination of their samples. Even young children
prefer to receive some information at their level of understanding.25,26
This right is limited by their ability to comprehend to what they are
agreeing to. This comprehension gradually increases as they acquire
more cognitive ability and more autonomy. Those monitoring
biobanks should develop procedures that allow a child to assent,
dissent and eventually consent or refuse as they mature.
Application. It is mandatory without any exceptions that at the
majority age the participant in principle can reconsent or withdraw
his/her consent. This may imply that young people should be
recontacted when they reach the age of majority. If the specific type
of biobank allows recontacting participants, they should consider
making young adults on the verge of majority aware that their
samples are being used in research and that it would be possible for
them to withdraw their samples from further research. Depending on
the setting, letters could be sent to participants when the age of legal
majority approaches. Alternatively the research could be advertised on
a dedicated official website with the possibility for participants to
contact the biobank or their treating physician regarding the use of
the samples. Or, at time of enrolment, parents could be asked to
inform their children as they grow older and be reminded to do so
when the age of legal majority approaches, if they have not done so
already. Although information technology is already being used in
certain cases for on line or at least electronic forms of informed consent
(See for example http://www.ncbi.nlm.nih.gov/pubmed/16127857, ftp://
128.95.1.178/tr/2000/12/UW-CSE-00-12-02.pdf, http://www.ukbiobank.
ac.uk/wp-content/uploads/2011/06/Consent_form.pdf and http://www.
ssi.dk/nyfoedte) in the web 2.0 era there would be many strategies
available to recontact parents or children.27
Where there is frequent contact between participants and the
research team, the maturity of minors and their capability to decide
for themselves whether they want to continue participating or not can
be assessed by the researchers, parents and minors together on a case-
by-case basis. If there was a one-time donation of the sample with no
further contact with the participant a fixed age threshold is most
realistic.
However, recontacting minors may not be feasible in all cases, for
example, because many people change addresses, or because anon-
ymised samples are used in epidemiological research. Therefore, the
duty to recontact could perhaps be done on a best effort basis.
If recontacting a minor is not possible, an ethics committee should
decide on the fate of the sample. Also, samples and information about
the samples are potentially shared with researchers in other jurisdic-
tions, making complete withdrawal of all information sometimes
impossible. In any case, parents and children should be informed
about the possible challenges of complete withdrawal at time of
enrolment.
Specific or broad consent
Principle. Next to determining who should give consent, it is
important to consider what content is necessary to ensure adequate
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consent. In debates about adult biobanks, authors have considered
whether so called ‘broad’ consent–consent to future unspecified
research is appropriate.28–30 Some have argued that as long as
participants have the right to withdraw their samples and that there
is clear research governance including ethical committee oversight and
involvement of stakeholders such as patient organisations, broad
consent is possible for adults. In the case of paediatric stored tissue
samples this issue is further complicated by the fact that parents give
consent for their children. Can parents be allowed to give broad
consent for any future research on their children’s samples until the
age of majority? On the one hand, as we stated before, minors, as
persons growing towards autonomy and acquiring their own values,
should be given the opportunity to express their choices. On the other
hand, it may also be administratively impractical to recontact minors
and/or their parents for each change in the research protocol.
Moreover, many participants would not want frequent recontact.
People may have different attitudes towards different aims and kinds
of science, however, there is much general support for research that
would lead to treatment or better understanding of medical conditions.
Less expressed support exists for fundamental research on genome
structures and functions, maybe because the clinical benefit is
more complicated to explain than the significance for medical condi-
tions. However, fundamental research may eventually also result in
knowledge advances that may allow medical progress without this
being foreseen. It may be permissible to assume that such research is
part of the original parental consent, although some disease categories
may be more sensitive than others, such as psychiatric diseases.
Application. It is a good policy to make parents and their older
children aware of the type of research done on their samples and give
them the opportunity to withdraw their participation. This will be
easier if the type of biobank entails frequent contact between
participants and researchers. In such cases, participants and their
parents may be notified personally of new research. In case of a
single donation of a sample or of epidemiological research on
anonymous samples, this is more difficult, if not impossible. Ethics
committees should be consulted before the start of sampling for the
biobank, but also when research changes considerably from the
original description given before the consent. The committee may
advice whether recontact is necessary. In any case, different media
including websites should be used to ensure transparency of the
research, especially for those cases where donors can no longer be
tracked.
Proportionality
Principle. When medical research has the potential to treat certain
diseases, researchers can appeal to the principle of solidarity to enrol
participants.31,32 However, such an appeal is restricted when
participants are minors, as they have a limited autonomy and
understanding and are therefore vulnerable. Any research exposure
should therefore involve only minimal risks.8,33 What does the term
risk entail in the context of biobanks?
Genetic information may reveal information about the health
status of the individual. Research that may discover this should
therefore be performed with clear governance and data-protection
procedures in place. Privacy risks should be addressed on two levels.
First, society in general should operate in a framework of fair
institutions and privacy laws. These frameworks need to be able to
help facing concrete situations in the evolving technological world.
The Data protection Directive (Directive 95/46/EC) that sets the legal
requirements in this respect in all EU countries is currently under
revision following a set of public consultations (http://ec.europa.eu/
justice/data-protection/index_en.htm). It has specific dispositions for
research. Second, the governance of the biobank is important and
should include appropriate data-protection policies. This is especially
the case when samples are shared with researchers outside the
biobank. For example, samples and data should be coded, so that
the identity of the donor is not available to the researcher using the
sample. Balancing the privacy of participants and research require-
ments is challenged by developments in science and technology. There
again information technologies may help implementing appropriate
procedures.34 Also, good governance assumes that citizens and patient
organisations have been involved and consulted in the setup of the
biobank. We assume that such baseline safeguards are already in place
or are taken into consideration.8,31 We admit that the requirement of
good governance is harder to control when samples are shared across
national borders, an issue which may be further complicated in the
case of paediatric biobanks, and which is still under discussion.35–38
Application. Empirical research has shown that respondents are
most concerned about the burden of non-therapeutic medical
research to children, especially the physical burden.7,39,40 Potential
burdens depend on the biobank in question: it may be less relevant in
research using collections that were gathered in a diagnostic or
screening context and that do not require further contact between
participants and researchers. However, if diagnostic or screening
samples are used, it should be confirmed that enough material
remains for follow-up of the original clinical purpose. If new samples
are required the procedures should cause the least physical and
psychological discomfort as possible. Also, non-physical burdens may
occur in genetic research, such as burdens associated with the
knowledge of certain genetic information.
Feedback of results
Principles. In biobanks, two types of results can be fed back. First,
aggregate results of a study can be sent to participants or published on
a website. Second, research may generate health information about
specific participants. Such information may be the direct result of the
research or may be generated as an incidental finding. We shall
discuss them both as ‘individual results’ in this section. We shall not
discuss here the feedback of results from direct observations, such as
blood pressure, because it is not the focus of the paper.
Debates around the feedback of individual results in the case of
adult biobanks41–47 distinguish three broad stances. (1) No individual
results are fed back to participants, because this might generate
anxiety while the results themselves may be insecure and preliminary
or because could enhance the therapeutic misconception. Moreover,
biobanks are also primary research tools and feeding back individual
results implies that too many resources would have to be allocated to
this feedback. (2) Participants are given a choice whether to receive
individual results or not. In this case, the communication may differ
according to the type of disease: early or late onset or whether the
finding concerns carrier status. In some research settings, for example
at NIH, the primary researchers are recontacted on the recent/new
results and are advised to contact the families. If the parents/patients
do wish to receive a final report they are asked to give new samples
(whenever possible) to test at a diagnostic laboratory or the results
should be confirmed with an independent sample. (3) Results are fed
back depending on their potential benefits: if a result has clinical
relevance and may modify the course of management it is fed back.
However, the complexity of interpretation and the difficulty of
determining the scientific validity and clinical utility of the results
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should not be underestimated.48 Feedback discussions10 should
debate both the right of participants to such information as well as
any duty that a researcher might have to provide it, either to the
parents or to the child’s physician.
As children do not enrol themselves in the research, the question
whether research findings are fed back needs addressing. As a
principle, parents are supposed to consider the best interest of their
child. Hence, they should not opt out of receiving information that is
relevant to the health of their children, if they decide to enrol their
children in non-therapeutic research. In this respect, the potential
benefits for the child in the case of certain diseases should prevail over
the right of the parent not to know. In the case of genetic research,
this may refer to early-onset treatable or preventable disorders, in
accordance with guidelines regarding genetic testing of children.49
Such discoveries at the present time are only applicable to genetic
conditions such as familial adenomatous polyposis or hypertrophic
cardiomyopathy, where preventive actions or actions for early
detection can be taken during childhood. Revealing information
about treatable or preventable conditions that are of adult onset
should usually be postponed until the young person can decide for
him or herself whether to receive such information.50 It is part of the
right of the minor to an open future that he or she can decide
whether or not certain genetic information is given to him or her.
However, if the genetic information is relevant for future reproductive
choices of the parents, one should find a way to inform them.
Moreover, some have suggested that the scope of certain genetic tests
for minors should be widened to include also severe, but non-
treatable/preventable diseases, to avoid medical Odysseys.51 Changes
in policies regarding paediatric genetic tests may affect the policy of
the biobank regarding the feedback of individual results.
Within the scope of the researcher’s duty, feedback of information
about early-onset preventable or treatable conditions may be more
advisable in the case of paediatric biobanks than in case of adult
biobanks, because of the fact that children do not enrol themselves
and are hence more vulnerable.
Application. The implementation of the duty to feedback early-onset
preventable or treatable conditions will depend on the type of the
biobank, and on the actual legal framework. It is dependent on the
type of collection, the feasibility of providing genetic counselling and
the possibility of checking the findings for clinical validity and utility.
On the one hand, studies involving children often involve more direct
contact between researchers and children and are done in a clinical
setting. If studies are done in a clinical setting, it may be unethical not
to inform the subject of results with actionable clinical implications.
On the other hand, epidemiological research that puts no burden on
children and implies no contact between the researcher and the child,
or where it may be harder to validate the findings clinically may be
exempted from this rule.
CONCLUSIONS
The inclusion of biological samples from minors in biobanks, and
their subsequent research use, may contribute to the knowledge and
treatment or prevention of many paediatric conditions. However, this
inclusion also raises ethical questions, which are not analogous to
those encountered in the use of tissue samples from adults or to the
issues associated with clinical trials. These ethical issues also have
policy implications. In this document we have laid down some issues
that should be considered when starting up a paediatric biobank or
when using existing collections of biological samples from children
for research. Issues include the need for parental consent, the scope of
parental consent and the duty to recontact young adults, and the right
of a child to assent or dissent. They also include the requirement of
minimal risk, be it physical, emotional or informational risk, and the
requirement that research should benefit other children or should not
be equally possible with adults. Also the question whether or not to
return individual results deserves special considerations when parti-
cipants are children. There may be more reason to return such results,
especially when the condition found is preventable or treatable in the
early years of life.
When developing a policy for paediatric biobanks, the type of
biobank in question is also relevant. Different requirements should be
taken into account when there is no frequent contact between
participant and researcher, or when there is no possibility for genetic
counselling. On the one hand, issues such as return of results or
recontact are impossible when samples are completely anonymised
which could be the case in large-scale epidemiological genetic
research. On the other hand, withholding relevant medical informa-
tion or not informing a child about research done on his or her DNA
may be unacceptable when there are frequent contacts between
researchers and participants or when the research is done in a clinical
context.
PRINCIPLES FOR GOOD PRACTICE
1. Genetic research on stored biological samples from minors should
only be done if the research questions cannot be answered by a
study of adults (subsidiarity principle).
2. The collection and use of biological samples and data from minors
should minimise physical and psychological burden.
3. The focus of who decides about the collection, storage and use of
samples gradually shifts from the parents to the minor as he or she
grows older and/or reaches the age of majority.
4. Minors should receive age-appropriate information about the
collection, storage and use of their samples, and a minor’s assent
or dissent should be respected.
5. Minors should be given the opportunity to contact researchers and
to withdraw their samples, if they so wish, when they are mature
enough or when they reach adulthood.
6. A best effort should be made to communicate the progress of
research. The purpose of ongoing research should be transparent,
either through direct communication with the participants or
through communication via for instance a website or newsletters.
7. Biobanks should have a policy about returning information about
preventable or treatable conditions of early onset when partici-
pants are minors. Details of this should be included in the consent
forms.
8. The right of parents to receive or not to receive genetic informa-
tion about their children is limited. In the rare case that
information about a preventable or treatable early-onset disease
is found, they should be notified regardless of their wishes
providing the findings are subject to assessment of clinical validity
and utility.
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